Author:
Michalik Stephan,Siegerist Florian,Palankar Raghavendra,Franzke Kati,Schindler Maximilian,Reder Alexander,Seifert Ulrike,Cammann Clemens,Wesche Jan,Steil Leif,Hentschker Christian,Gesell-Salazar Manuela,Reisinger Emil,Beer Martin,Endlich Nicole,Greinacher Andreas,Völker Uwe
Abstract
Vector-based SARS-CoV-2 vaccines have been associated with vaccine- induced thrombosis with thrombocytopenia syndrome (VITT/TTS), but the causative factors are still unresolved. We comprehensively analyzed the ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Johnson and Johnson) vaccines. ChAdOx1 nCoV-19 contains significant amounts of host cell protein impurities, including functionally active proteasomes, and adenoviral proteins. A much smaller amount of impurities was found in Ad26.COV2.S. Platelet factor 4 formed complexes with ChAdOx1 nCoV-19 constituents, but not with purified virions from ChAdOx1 nCoV-19 or with Ad26.COV2.S. Vascular hyperpermeability was induced by ChAdOx nCoV-19 but not by Ad26.COV2.S. These differences in impurities together with EDTAinduced capillary leakage might contribute to the higher incidence rate of VITT associated with ChAdOx1 nCoV-19 compared to Ad26.COV2.S.
Publisher
Ferrata Storti Foundation (Haematologica)
Reference29 articles.
1. Sadoff J, Gray G, Vandebosch A. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201.
2. Voysey M, Clemens SAC, Madhi SA. Safety and efficacy of the ChAdOx1 nCoV- 19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397(10269):99-111.
3. See I, Lale A, Marquez P. Case series of thrombosis with thrombocytopenia syndrome following COVID-19 vaccination— United States, December 2020–August 2021.Publisher
4. Chevassut T, Hunt BJ, Pavord S. VITT, COVID-19 and the Expert Haematology Panel: the story of how the UK responded to emerging cases of vaccine-induced immune thrombocytopenia and thrombosis during the vaccination programme. Clin Med (Lond). 2021; 21(6):e600-e602.
5. Paul-Ehrlich-Institut Germany. Sicherheitsbericht: Verdachtsfälle von Nebenwirkungen und Impfkomplikationen nach Impfung zum Schutz vor COVID-19 seit Beginn der Impfkampagne am 27.12.2020 bis zum 30.09.2021 [accessed Dec 6, 2021].Publisher
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献